DIGENESIS
Dead / Abandoned — Abandoned — failure to respond (as of 21 Jun 2022)
What this means for you
This application is over — abandoned 07 Jun 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88662693
- Mark type
- Stylized text
- Filed
- 21 Oct 2019
- Published for opposition
- 18 Aug 2020
- Abandoned
- 07 Jun 2022
- Attorney of record
- Charles R Halloran
Goods and services
- Class 035 — Advertising and business services: business consulting and management in the fields of medical research, pharmaceutical development and clinical trials for business purposes; business consulting and management in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes; business consulting and management in the field of pharmaceutical development, namely, management and compilation of computerized databases in the field of pharmaceutical development for business purposes; business consulting and management in the field of pharmaceutical development, namely, management and compilation of computerized databases in the field of medical research for business purposes; all of the foregoing excluding the field of digenesis
- Class 042 — Scientific and technological services: providing medical and scientific research information in the fields of medical research, pharmaceutical development and clinical trials; consulting services for others in the field of design and planning of clinical trials; consulting services for others in the fields of medical research and pharmaceutical development; consulting services for others in the fields of medical research and pharmaceutical development, namely, providing digital models of patients for use as simulated control subjects; consulting services for others in the field of design and planning of clinical trials, namely, providing digital models of patients for use as simulated control subjects for clinical trials; providing data analytics and artificial intelligence in the nature of non-downloadable software, for use in the design and planning of clinical trials; providing data analytics and artificial intelligence in the nature of non-downloadable software, for use in medical research and pharmaceutical development; providing data analytics and artificial intelligence in the nature of non-downloadable software, for use in the life sciences field for the purpose of research, development, and commercialization; providing a website featuring educational information in the fields of medical research, pharmaceutical development, clinical trials and artificial intelligence; all of the foregoing excluding the field of digenesis
Owner
- UNLEARN.AI, INC., San Francisco, CA, US
- UNLEARN.AI, INC., San Francisco, CA, US
Prosecution history
- 21 Jun 2022 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 21 Jun 2022 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 06 Dec 2021 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 06 Dec 2021 — NON-FINAL ACTION E-MAILED
- 06 Dec 2021 — SU - NON-FINAL ACTION - WRITTEN
- 09 Nov 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 20 Oct 2021 — USE AMENDMENT FILED
- 05 Nov 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 20 Oct 2021 — TEAS STATEMENT OF USE RECEIVED
- 12 Oct 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Oct 2021 — SOU EXTENSION 2 GRANTED
- 08 Oct 2021 — SOU EXTENSION 2 FILED
- 08 Oct 2021 — SOU TEAS EXTENSION RECEIVED
- 14 Apr 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Apr 2021 — SOU EXTENSION 1 GRANTED